[
  {
    "ts": "2025-11-14T00:07:43+00:00",
    "headline": "Merck nears deal for flu-prevention biotech Cidara",
    "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
    "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "feb600a5-727c-382c-96f3-701294a4a06c",
      "content": {
        "id": "feb600a5-727c-382c-96f3-701294a4a06c",
        "contentType": "STORY",
        "title": "Merck nears deal for flu-prevention biotech Cidara",
        "description": "",
        "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
        "pubDate": "2025-11-14T00:07:43Z",
        "displayTime": "2025-11-14T00:07:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T04:20:22+00:00",
    "headline": "Merck (MRK) Delivers Strong Q3 2025 Earnings as Oncology Sales Drive Revenue Growth",
    "summary": "Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co. Inc. (NYSE:MRK) announced its Q3 2025 earnings, showing better-than-expected financial results despite uneven product portfolio performance. The company’s revenue of $17.3 billion crossed analyst estimates of $16.98 billion, while its EPS […]",
    "url": "https://finance.yahoo.com/news/merck-mrk-delivers-strong-q3-042022417.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ab230763-a948-3ac0-b59c-ca92269a19fb",
      "content": {
        "id": "ab230763-a948-3ac0-b59c-ca92269a19fb",
        "contentType": "STORY",
        "title": "Merck (MRK) Delivers Strong Q3 2025 Earnings as Oncology Sales Drive Revenue Growth",
        "description": "",
        "summary": "Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co. Inc. (NYSE:MRK) announced its Q3 2025 earnings, showing better-than-expected financial results despite uneven product portfolio performance. The company’s revenue of $17.3 billion crossed analyst estimates of $16.98 billion, while its EPS […]",
        "pubDate": "2025-11-14T04:20:22Z",
        "displayTime": "2025-11-14T04:20:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7f572bd67da146fcf0c740d8b0a50bb6",
          "originalWidth": 375,
          "originalHeight": 375,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6vTDauMGAVR2c3f8Np70vg--~B/aD0zNzU7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7f572bd67da146fcf0c740d8b0a50bb6.cf.webp",
              "width": 375,
              "height": 375,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/68elpyOJAayKU37_DKuoww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7f572bd67da146fcf0c740d8b0a50bb6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-delivers-strong-q3-042022417.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-delivers-strong-q3-042022417.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T00:07:43+00:00",
    "headline": "Merck nears $9.2bn deal for flu-prevention biotech Cidara",
    "summary": "Merck is nearing a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu,...",
    "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "feb600a5-727c-382c-96f3-701294a4a06c",
      "content": {
        "id": "feb600a5-727c-382c-96f3-701294a4a06c",
        "contentType": "STORY",
        "title": "Merck nears $9.2bn deal for flu-prevention biotech Cidara",
        "description": "",
        "summary": "Merck is nearing a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu,...",
        "pubDate": "2025-11-14T00:07:43Z",
        "displayTime": "2025-11-14T00:07:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T09:30:00+00:00",
    "headline": "Recombinant Human Fibroblast Growth Factor Global Market Forecast 2025-2030: Markets Benefit from Strategic Investments and Collaborations",
    "summary": "Recombinant human fibroblast growth factors offer growth prospects in regenerative medicine and cosmetics, driven by efficient production systems. Key opportunities arise from applications in wound healing, tissue engineering, and cosmetics. Notable firms include Thermo Fisher and Merck.Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The \"Recombinant Human Fibroblast Growth Factor Market - Global Forecast 2025-2030\" report has been added to ResearchAndMarkets.com's offering. Recombinant human fibrobla",
    "url": "https://finance.yahoo.com/news/recombinant-human-fibroblast-growth-factor-093000334.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "fa2fb38e-b20d-38f2-9b85-dde3215bfff9",
      "content": {
        "id": "fa2fb38e-b20d-38f2-9b85-dde3215bfff9",
        "contentType": "STORY",
        "title": "Recombinant Human Fibroblast Growth Factor Global Market Forecast 2025-2030: Markets Benefit from Strategic Investments and Collaborations",
        "description": "",
        "summary": "Recombinant human fibroblast growth factors offer growth prospects in regenerative medicine and cosmetics, driven by efficient production systems. Key opportunities arise from applications in wound healing, tissue engineering, and cosmetics. Notable firms include Thermo Fisher and Merck.Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The \"Recombinant Human Fibroblast Growth Factor Market - Global Forecast 2025-2030\" report has been added to ResearchAndMarkets.com's offering. Recombinant human fibrobla",
        "pubDate": "2025-11-14T09:30:00Z",
        "displayTime": "2025-11-14T09:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/recombinant-human-fibroblast-growth-factor-093000334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/recombinant-human-fibroblast-growth-factor-093000334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TMO"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T12:35:47+00:00",
    "headline": "Merck agrees $9.2bn deal for flu-prevention biotech Cidara",
    "summary": "Merck has agreed a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antiviral that protects against flu, after overcoming...",
    "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "feb600a5-727c-382c-96f3-701294a4a06c",
      "content": {
        "id": "feb600a5-727c-382c-96f3-701294a4a06c",
        "contentType": "STORY",
        "title": "Merck agrees $9.2bn deal for flu-prevention biotech Cidara",
        "description": "",
        "summary": "Merck has agreed a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antiviral that protects against flu, after overcoming...",
        "pubDate": "2025-11-14T12:35:47Z",
        "displayTime": "2025-11-14T12:35:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T12:04:47+00:00",
    "headline": "Merck Agrees to Acquire Cidara Therapeutics for $9.2 Billion",
    "summary": "Merck (MRK) said Friday it has agreed for a subsidiary to acquire all outstanding shares of Cidara T",
    "url": "https://finance.yahoo.com/news/merck-agrees-acquire-cidara-therapeutics-120447169.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "92828353-2716-330b-bb59-7dbf62fb5150",
      "content": {
        "id": "92828353-2716-330b-bb59-7dbf62fb5150",
        "contentType": "STORY",
        "title": "Merck Agrees to Acquire Cidara Therapeutics for $9.2 Billion",
        "description": "",
        "summary": "Merck (MRK) said Friday it has agreed for a subsidiary to acquire all outstanding shares of Cidara T",
        "pubDate": "2025-11-14T12:04:47Z",
        "displayTime": "2025-11-14T12:04:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-agrees-acquire-cidara-therapeutics-120447169.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-agrees-acquire-cidara-therapeutics-120447169.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T11:45:00+00:00",
    "headline": "Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent",
    "summary": "RAHWAY, N.J. & SAN DIEGO, Calif., November 14, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) (\"Cidara\"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.",
    "url": "https://finance.yahoo.com/news/merck-acquire-cidara-therapeutics-inc-114500346.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "fa6bd72d-451b-31bb-9f2c-cf6c8987aa19",
      "content": {
        "id": "fa6bd72d-451b-31bb-9f2c-cf6c8987aa19",
        "contentType": "STORY",
        "title": "Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent",
        "description": "",
        "summary": "RAHWAY, N.J. & SAN DIEGO, Calif., November 14, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) (\"Cidara\"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.",
        "pubDate": "2025-11-14T11:45:00Z",
        "displayTime": "2025-11-14T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/829d64332a6e170059b457fe1a5d139d",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NBRpxxnK.lbk.z1TrNfVUw--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/829d64332a6e170059b457fe1a5d139d.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JgqWJe4xEVRowNh9qqNQrg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/829d64332a6e170059b457fe1a5d139d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-acquire-cidara-therapeutics-inc-114500346.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-acquire-cidara-therapeutics-inc-114500346.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T13:24:07+00:00",
    "headline": "Do You Believe in Merck & Co.’s (MRK) Upside Potential?",
    "summary": "Antipodes Partners recently published its “Antipodes Global Value Strategy” third-quarter 2025 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. In the quarter, global equities rose positively, supported by easing trade tensions, excitement around AI, and expectations of rate cuts by the […]",
    "url": "https://finance.yahoo.com/news/believe-merck-co-mrk-upside-132407374.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "1ac9bc22-adbc-3733-9292-aceead01b7f8",
      "content": {
        "id": "1ac9bc22-adbc-3733-9292-aceead01b7f8",
        "contentType": "STORY",
        "title": "Do You Believe in Merck & Co.’s (MRK) Upside Potential?",
        "description": "",
        "summary": "Antipodes Partners recently published its “Antipodes Global Value Strategy” third-quarter 2025 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. In the quarter, global equities rose positively, supported by easing trade tensions, excitement around AI, and expectations of rate cuts by the […]",
        "pubDate": "2025-11-14T13:24:07Z",
        "displayTime": "2025-11-14T13:24:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4c2d50f14c73c26f6188d27970ea7976",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Why Merck & Co (MRK) Continues to Rank Among the Most Profitable Dividend Stocks",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oa9Va5k1p.K45fG16hN8EA--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4c2d50f14c73c26f6188d27970ea7976.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Jx7jyTUIaHl16z0st88IEw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4c2d50f14c73c26f6188d27970ea7976.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/believe-merck-co-mrk-upside-132407374.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/believe-merck-co-mrk-upside-132407374.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T13:19:00+00:00",
    "headline": "This Biotech Stock Is Soaring 100%. Merck Is Buying It.",
    "summary": "Shares of  Cidara Therapeutics  soared Friday after  Merck & Co.  agreed to acquire the biotechnology company for $9.2 billion.  Merck, the New Jersey-based pharmaceutical giant, will pay Cidara stockholders $221.50 a share in the all-cash deal.  Cidara stock was up 103% to $215.50 in premarket trading Friday after closing at $105.99 on Thursday.",
    "url": "https://www.barrons.com/articles/cidara-therapeutics-stock-merck-deal-adaed806?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "c728677b-aa7e-3aba-b4b2-dea586309486",
      "content": {
        "id": "c728677b-aa7e-3aba-b4b2-dea586309486",
        "contentType": "STORY",
        "title": "This Biotech Stock Is Soaring 100%. Merck Is Buying It.",
        "description": "",
        "summary": "Shares of  Cidara Therapeutics  soared Friday after  Merck & Co.  agreed to acquire the biotechnology company for $9.2 billion.  Merck, the New Jersey-based pharmaceutical giant, will pay Cidara stockholders $221.50 a share in the all-cash deal.  Cidara stock was up 103% to $215.50 in premarket trading Friday after closing at $105.99 on Thursday.",
        "pubDate": "2025-11-14T13:19:00Z",
        "displayTime": "2025-11-14T13:19:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/c728677b-aa7e-3aba-b4b2-dea586309486/this-biotech-stock-is-soaring.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/88ee0a7cbc0a516285f366b85301cad2",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/baMr.C9w0JfSEo6imng9aw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/88ee0a7cbc0a516285f366b85301cad2.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/16ycysYam7k9cLJdQaRr4A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/88ee0a7cbc0a516285f366b85301cad2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/cidara-therapeutics-stock-merck-deal-adaed806?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T12:57:24+00:00",
    "headline": "Stocks to Watch Friday: Applied Materials, Nvidia, Cidara, Warner Bros.",
    "summary": "↘️ Applied Materials (AMAT): The chip-equipment maker's quarterly results and forecasts for this quarter topped expectations, spurred by the AI boom. Shares skidded 6.5% in premarket trading, however, as a broader tech selloff looked poised to continue.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-14-2025/card/stocks-to-watch-friday-applied-materials-nvidia-warner-bros--u4Yrx3bIUdt4HrktoRLp?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "61736e40-a7b9-3740-9c5c-f8ea7c76b1ed",
      "content": {
        "id": "61736e40-a7b9-3740-9c5c-f8ea7c76b1ed",
        "contentType": "STORY",
        "title": "Stocks to Watch Friday: Applied Materials, Nvidia, Cidara, Warner Bros.",
        "description": "",
        "summary": "↘️ Applied Materials (AMAT): The chip-equipment maker's quarterly results and forecasts for this quarter topped expectations, spurred by the AI boom. Shares skidded 6.5% in premarket trading, however, as a broader tech selloff looked poised to continue.",
        "pubDate": "2025-11-14T12:57:24Z",
        "displayTime": "2025-11-14T12:57:24Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/61736e40-a7b9-3740-9c5c-f8ea7c76b1ed/stocks-to-watch-friday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/3cd87e4655c7a6f84655b734289e98db",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DuZVMMPCCm1AnTmbyP9ikQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/3cd87e4655c7a6f84655b734289e98db.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1zGwFFg0M3XpqvUvCEkyzA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/3cd87e4655c7a6f84655b734289e98db.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-14-2025/card/stocks-to-watch-friday-applied-materials-nvidia-warner-bros--u4Yrx3bIUdt4HrktoRLp?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CFRHF"
            },
            {
              "symbol": "CFRUY"
            },
            {
              "symbol": "BHP"
            },
            {
              "symbol": "BHPLF"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "AMAT"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "CMCSA"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T12:19:00+00:00",
    "headline": "Merck to Buy Cidara Therapeutics in $9.2 Billion Deal",
    "summary": "Merck & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker’s respiratory portfolio.",
    "url": "https://www.wsj.com/health/pharma/merck-to-buy-cidara-therapeutics-in-9-2-billion-deal-9fbfdde7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "86658250-f352-3543-8fdb-34d938ec2e43",
      "content": {
        "id": "86658250-f352-3543-8fdb-34d938ec2e43",
        "contentType": "STORY",
        "title": "Merck to Buy Cidara Therapeutics in $9.2 Billion Deal",
        "description": "",
        "summary": "Merck & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker’s respiratory portfolio.",
        "pubDate": "2025-11-14T12:19:00Z",
        "displayTime": "2025-11-14T12:19:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/86658250-f352-3543-8fdb-34d938ec2e43/merck-to-buy-cidara.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/310086984904301c3c849e3dfd1dc2d4",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s9oC2bmR2x6uMnXgsSi8GQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/310086984904301c3c849e3dfd1dc2d4.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t0alJhM7zYBYHbubSwZ9Cw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/310086984904301c3c849e3dfd1dc2d4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/merck-to-buy-cidara-therapeutics-in-9-2-billion-deal-9fbfdde7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]